Palisade Bio Transforms GIFocused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma Inc for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Carlsbad,CA, Sept. 06, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it has entered into a licensing agreement with Giiant Pharma, Inc. (“Giiant”). The license provides the Company with the…Read More